Clinical trials: RAS Wild Type
Metastatic Colorectal Cancer
Pharmacokinetics and Metabolic Activation of Capecitabine
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).
- Trial name
- NCT01579357
- Testing
- blood samples
- Where
- 3 sites in Austria
- Volunteers
- 24 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Colorectal Cancer
Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer
To explore the efficacy and safety of pembrolizumab in combination with bevacizumab and CapeOX neoadjuvant therapy for the treatment of RAS-mutated, BRAF wild-type, microsatellite-stabilized, locally advanced colorectal cancer.
- Trial name
- NCT06550453
- Testing
- Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- yangjianjun
Colorectal Cancer, KRAS Wildtype
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with KRAS, NRAS, or…
- Conditions
- Colorectal Cancer, KRAS Wildtype, NRAS Wildtype, BRAF Wildtype
- Trial name
- NCT02399943
- Testing
- Trametinib, Panitumumab
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of…
- Trial name
- NCT01057017
- Testing
- intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brown University
Advanced Colorectal Cancer
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
A-REPEAT (Anti-Epidermal Growth Factor Receptor -EGFR- rechallenge and plasma genotyping of patients with advanced colorectal tumors) is a Greek, investigator-initiated, single arm open-label phase II study of anti-EGFR therapy…
- Trial name
- A-REPEAT (NCT03311750)
- Testing
- Panitumumab
- Where
- 8 sites in Cyprus, Greece
- Volunteers
- 23 people
- Sponsor
- Hellenic Cooperative Oncology Group
Colorectal Cancer
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in…
- Trial name
- CELIM2 (NCT01802645)
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 15 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Technische Universität Dresden
Rectal Adenocarcinoma, High-Risk Cancer
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRIT (NCT06908031)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cancer Colorectal
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
- Trial name
- CETIDYL (NCT04189055)
- Testing
- Cetuximab, Irinotecan
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Metastatic Colorectal Cancer
ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line
This is a national, multicentric, prospective, observational trial. The decision to prescribe FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab must have been freely taken by the clinician prior to the study…
- Trial name
- SILQ (NCT02624895)
- Where
- 31 sites in Italy
- Volunteers
- 296 people
- Sponsor
- Amgen
Colorectal Cancer, Liver Metastases
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in…
- Trial name
- NCT06280495
- Testing
- Oxaliplatin, Fluorouracil, Serplulimab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Rectum Cancer
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients
response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer
- Trial name
- NCT00964457
- Testing
- cetuximab
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Colo-rectal Cancer, RAS Wild-type
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated.
- Conditions
- Colo-rectal Cancer, RAS Wild-type, UICC III, UICC II + RF
- Trial name
- 2016-003295-46 (NCT03263663)
- Testing
- targeted substance according to the avatar model
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- PD Dr. med. Volker Heinemann
Metastatic Colorectal Cancer
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
The Nordic FLOX-regime consists of a combination of bolus 5-FU, leukovorin and oxaliplatin (Eloxatin®). Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR).
- Trial name
- NCT00660582
- Testing
- Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 152 people
- Sponsor
- Per Pfeiffer
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients.
- Trial name
- TRIPLETE (NCT03231722)
- Testing
- Panitumumab, Irinotecan, Oxaliplatin
- Where
- 4 sites in Italy
- Volunteers
- 435 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.
- Trial name
- NCT05619172
- Testing
- Nanrilkefusp alfa, Cetuximab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 16 people
- Sponsor
- SOTIO Biotech AG